Actelion Ltd
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 45 (Table of Contents)
Published: 4 Mar-2004
DOI: 10.3833/pdr.v2004.i45.827 ISSN: 1756-7874
Section: Company Profile
Fulltext:
Abstract
Actelion aspires to exploit the potential of endothelin receptor antagonism (ERA) as an approach to new treatments for cardiovascular disease, but the company’s research activities have subsequently expanded through investigating other G-protein coupled receptors and aspartic proteases in additional therapeutic areas...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS